How NHS England Plans To Charge Companies A ‘Fair Price’ For Access To Its Health Data
Executive Summary
Setting a specific monetary value for data is complex, says the National Health Service, which has published a new framework to ensure that fair terms are agreed for the use of public resources in data partnerships, including a fair share of any profits generated from partnerships that are commercialized.
You may also be interested in...
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, including Genmab/AbbVie’s Tepkinly, for treating adult patients with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.
Europe’s Proposed Chemical Ban Could Hit Many Thousands Of Global Marketing Authorizations
Drug manufacturing in the EU would grind to a halt in under three years if a proposal to restrict per- and polyfluoroalkyl substances in the European Economic Area is implemented in its current form, says industry group EFPIA.
New EU Filings
Givinostat, Italfarmaco’s investigational treatment for Duchenne muscular dystrophy, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.